Many Payers Will Parity Prefer Xtandi, Chemotherapy in mHSPC
In December, the FDA gave another indication to Pfizer Inc. and Astellas Pharma Inc.’s Xtandi (enzalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer. Many commercial payers have indicated that they may parity prefer Xtandi with chemotherapy for this indication, which is also known as metastatic hormone-sensitive prostate cancer (mHSPC), according to Zitter Insights research.
Drug Is Used in Other Prostate Cancers
The Dec. 16 approval, which had priority review, is Xtandi’s third in prostate cancer (RSP 1/20, p. 8). The FDA initially approved the drug in August 2012 for metastatic castration-resistant prostate cancer (RSP 9/12, p. 9); approval for use in nonmetastatic castration-resistant prostate cancer came in July 2018 (RSP 7/18, p. 10).
Related Posts

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE